GE HealthCare (Nasdaq: GEHC) has reached an agreement to acquire the remaining 50% stake in Nihon Medi-Physics Co., Ltd. (NMP) from Sumitomo Chemical (TYO: 4005), giving it full ownership of…
Projected to surpass $38 billion in value by 2032, artificial intelligence (AI) simulations—particularly digital twins—are reshaping the healthcare landscape. These virtual replicas of individuals possess an uncanny ability to replicate…
Despite criticism stemming from contentious biomarkers and failed confirmatory trials, the FDA’s accelerated approval pathway continues to drive therapeutic innovation for some of the world’s most complex and pressing medical…
Technological breakthroughs and deeper insights into glioblastoma are revitalizing efforts to tackle this aggressive brain tumor. Companies like Merck, Kazia Therapeutics, CorriXR Therapeutics, and others are leading the charge, raising…
At the 2024 Annual Meeting of the Radiological Society of North America (RSNA), held December 1-4 in Chicago, GE HealthCare (Nasdaq: GEHC) is presenting over 40 groundbreaking innovations. These include…
Laser Photonics Corporation a global leader in the development of industrial laser systems for material processing applications, has announced the launch of a new research and development (R&D) initiative aimed…
Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical-stage botanical pharmaceutical company specializing in the development of unique botanical pharmaceutical and cosmeceutical products, has announced its financial…
The global Generic Injectables market, valued at $95.2 billion in 2023, is on a strong growth trajectory and is projected to reach $206.8 billion by 2030, growing at a CAGR…
Bayer has inaugurated Bayer Co.Lab Berlin, a state-of-the-art life science incubator located at the company’s Pharmaceuticals Division Global Headquarters Campus. Positioned near leading research and clinical institutions in Berlin, the…
UCB, a global biopharmaceutical leader, has announced the successful completion of its sale, divestment, and licensing agreement for its mature neurology and allergy portfolio in China. The transaction, valued at…
BeiGene has announced that the European Commission has approved TEVIMBRA® (tislelizumab) in combination with chemotherapy as a first-line treatment for two aggressive cancer types: esophageal squamous cell carcinoma (ESCC) and…
Nearly five years after the onset of COVID-19, a new report from the World Health Organization (WHO) reveals limited progress in closing critical gaps in infection prevention and control (IPC)…